Drugs / VBI-1501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02826798 | Jun → Sep 2016 | cytomegalovirus infection | VBI Vaccines Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2018-10-02 | VBI Vaccines Inc. | Results VBI Vaccines’ Late-Breaker Cytomegalovirus Abstract Chosen for Oral Presentation at IDWeek 2018 vbivaccines.com ↗
This multicenter first-in-humans study was conducted in collaboration with the Canadian Immunization Research Network (CIRN), and showed that VBI-1501 was safe and well tolerated at all doses tested. |
| 2018-05-10 | VBI Vaccines Inc. | Results VBI Vaccines Announces Positive Final Phase 1 Study Results of Preventative CMV Vaccine vbivaccines.com ↗
The final Phase 1 study results demonstrated that VBI-1501 was safe and well-tolerated at all doses. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-10-02 | VBI Vaccines Inc. | VBI Vaccines’ Late-Breaker Cytomegalovirus Abstract Chosen for Oral Presentation at IDWeek 2018 vbivaccines.com ↗ |
| 2018-05-10 | VBI Vaccines Inc. | VBI Vaccines Announces Positive Final Phase 1 Study Results of Preventative CMV Vaccine vbivaccines.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VBI-1501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02826798 ↗ |
| Modality | Vaccine | “an enveloped virus-like particle (eVLP) vaccine expressing a modified form of the CMV glycoprotein B (gB)” PMID 38142214 ↗ Dec 2023 |
| Route | Intramuscular | “VBI-1501: 1.0 μg without alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168” NCT02826798 ↗ |